Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2015 Jan-Feb;17(1):124-34.
doi: 10.4103/1008-682X.137685.

Efficacy and safety of solifenacin plus tamsulosin oral controlled absorption system in men with lower urinary tract symptoms: a meta-analysis

Ming-Chao Li, Zheng-Yun Wang, Jun Yang, Xiao-Lin Guo, Tao Wang  1 , Shao-Gang Wang, Ji-Hong Liu  1 , Zhang-Qun Ye
Affiliations
Meta-Analysis

Efficacy and safety of solifenacin plus tamsulosin oral controlled absorption system in men with lower urinary tract symptoms: a meta-analysis

Ming-Chao Li et al. Asian J Androl. 2015 Jan-Feb.

Abstract

We performed a meta-analysis to compare treatment with a combination of solifenacin plus tamsulosin oral controlled absorption system (TOCAS) with placebo or TOCAS monotherapy. The aim of the meta-analysis was to clarify the efficacy and safety of the combination treatments method for lower urinary tract symptoms (LUTS). We searched for trials of men with LUTS that were randomized to combination treatment compared with TOCAS monotherapy or placebo. We pooled data from three placebo-controlled trials meeting inclusion criteria. Primary outcomes of interest included changes in International Prostate Symptom Score (IPSS) and urinary frequency. We also assessed postvoid residual, maximum urinary flow rate, incidence of urinary retention (UR), adverse events. Data were pooled using random or fixed effect models for continuous outcomes and the Mantel-Haenszel method to generate risk ratio. Reductions in IPSS storage subscore and total urgency and frequency score (TUFS) were observed with solifenacin 6 mg plus TOCAS compared with placebo (P< 0.0001 and P< 0.0001, respectively). Reductions in IPSS storage subscore and TUFS were observed with solifenacin 9 mg plus TOCAS compared with placebo (P = 0.003 and P= 0.0006, respectively). Reductions in TUFS was observed with solifenacin 6 mg plus TOCAS compared with TOCAS (P = 0.01). Both combination treatments were well tolerated, with low incidence of UR. Solifenacin 6 mg plus TOCAS significantly improved total IPSS, storage and voiding symptoms compared with placebo. Solifenacin 6 mg plus TOCAS also improved storage symptoms compared with TOCAS alone. There was no additional benefit of solifenacin 9 mg compared with 6 mg when used in combination with TOCAS.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Study selection process for trials included in meta-analysis.
Figure 2
Figure 2
Pooled data analysis of total International Prostate Symptom Score.
Figure 3
Figure 3
Pooled data analysis of International Prostate Symptom Score storage subscore.
Figure 4
Figure 4
Pooled data analysis of International Prostate Symptom Score voiding subscore.
Figure 5
Figure 5
Pooled data analysis of total urgency and frequency score.
Figure 6
Figure 6
Pooled data analysis of micturitions per 24 h.
Figure 7
Figure 7
Pooled data analysis of volume voided per micturition.
Figure 8
Figure 8
Pooled data analysis of urgency episodes per 24 h.
Figure 9
Figure 9
Pooled data analysis of postvoid residual volume.
Figure 10
Figure 10
Pooled data analysis of urinary retention.
Figure 11
Figure 11
Pooled data analysis of dry mouth.
Figure 12
Figure 12
Pooled data analysis of constipation.
See this image and copyright information in PMC

References

    1. Sexton CC, Coyne KS, Kopp ZS, Irwin DE, Milsom I, et al. The overlap of storage, voiding and postmicturition symptoms and implications for treatment seeking in the USA, UK and Sweden: EpiLUTS. BJU Int. 2009;103(Suppl 3):12–23. - PubMed
    1. Lee SH, Chung BH, Kim SJ, Kim JH, Kim JC, et al. Initial combined treatment with anticholinergics and a-blockers for men with lower urinary tract symptoms related to BPH and overactive bladder: a prospective, randomized, multi-center, double-blind, placebo-controlled study. Prostate Cancer Prostatic Dis. 2011;14:320–5. - PubMed
    1. Coyne KS, Sexton CC, Irwin DE, Kopp ZS, Kelleher CJ, et al. The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well-being in men and women: results from the EPIC study. BJU Int. 2008;101:1388–95. - PubMed
    1. Oelke M, Bachmann A, Descazeaud A, Emberton M, Gravas S, et al. EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol. 2013;64:118–40. - PubMed
    1. Filson CP, Hollingsworth JM, Clemens JQ, Wei JT. The efficacy and safety of combined therapy with a-blockers and anticholinergics for men with benign prostatic hyperplasia: a meta-analysis. J Urol. 2013;190:2153–60. - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources